BAXTER INTERNATIONAL INC. (BAX)
Baxter International provides a broad portfolio of essential healthcare products, including sterile IV solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, generic injectables, surgical hemostat and sealant products, smart bed systems, patient monitoring and respiratory health devices.
| Ticker | BAX |
|---|
| Company | BAXTER INTERNATIONAL INC. |
|---|
| Exchange | NYSE |
|---|
| Headquarters | DEERFIELD, IL |
|---|
Income statement — period ending 2026-06-30
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $109,000,000 |
|---|
| Cost of Goods and Services Sold | $1,928,000,000 |
|---|
| Earnings Per Share, Basic | 0 USD/shares |
|---|
| Earnings Per Share, Diluted | 0 USD/shares |
|---|
| Gross Profit | $1,032,000,000 |
|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $158,000,000 |
|---|
| Income Tax Expense (Benefit) | $23,000,000 |
|---|
| InterestExpenseNonoperating | -$13,000,000 |
|---|
| Net Income (Loss) Attributable to Parent | $126,000,000 |
|---|
| Net Income (Loss) Attributable to Noncontrolling Interest | $0 |
|---|
| Operating Income (Loss) | $217,000,000 |
|---|
| Other Nonoperating Income (Expense) | $5,000,000 |
|---|
| Other Operating Income (Expense), Net | $49,000,000 |
|---|
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $126,000,000 |
|---|
| Research and Development Expense | $129,000,000 |
|---|
| Restructuring Charges | $2,000,000 |
|---|
| Revenue from Contract with Customer, Excluding Assessed Tax | $2,960,000,000 |
|---|
| Selling, General and Administrative Expense | $735,000,000 |
|---|
| Share-based Payment Arrangement, Noncash Expense | $43,000,000 |
|---|
| Weighted Average Number of Shares Outstanding, Diluted | 518,000,000 shares |
|---|
| Weighted Average Number of Shares Outstanding, Basic | 517,000,000 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro